皮肤病沈阳哪家医院好-【沈阳肤康皮肤病医院】,decjTquW,沈阳哪里治疗毛囊炎比较好,沈阳肤康治灰指甲好吗,沈阳治疗痤疮得多少钱,在沈阳治荨麻疹需要多少钱啊,沈阳看黄褐斑比较好的医院在哪,沈阳看青春痘到哪家医院 好

WASHINGTON, May 20 (Xinhua) -- The U.S. Food and Drug Administration (FDA) on Friday approved Sutent to treat patients with progressive neuroendocrine cancerous tumors located in the pancreas that cannot be removed by surgery or that have spread to other parts of the body.Neuroendocrine tumors found in the pancreas are slow-growing and rare. It is estimated that there are fewer than 1,000 new cases in the United States each year.This is the second new approval by the FDA to treat patients with this disease. On May 5, the agency approved Afinitor."FDA believes it is important to provide cancer patients with as many treatment options as possible," said Richard Pazdur, director of the Office of Oncology Drug Products in the FDA's Center for Drug Evaluation and Research. "The agency is committed to working with companies to bring innovative new therapies to the market and encourages companies to continue exploring additional uses for approved products."The safety and effectiveness of Sutent was established in a single study of 171 patients with metastatic (late-stage) or locally advanced (disease that could not be removed with surgery) disease who received Sutent or a placebo (sugar pill). The study was designed to measure the length of time a patient lived before their disease spread or worsened (progression-free survival).Results from the study demonstrate that Sutent provided benefit to patients by prolonging the median length of time they lived without the cancer spreading or worsening to 10.2 months compared to 5.4 months for patients who received placebo.In patients treated with Sutent for neuroendocrine pancreatic tumors, the most commonly reported side effects included diarrhea, nausea, vomiting, fatigue, anorexia, high blood pressure, energy loss, stomach pain, changes in hair color, inflammation of the mouth, and a decrease in infection-fighting white blood cells.Sutent is marketed by New York City-based Pfizer.
BEIJING, Feb. 10 (Xinhua) -- The Chinese currency, or the yuan, on Thursday rose to a fresh high of 6.5849 against the U.S. dollar, according to the China Foreign Exchange Trading System.The central parity rate of the yuan, or RMB, was 1 basis point higher than the previous record of 6.585 set on Feb. 9, the previous trading day.The central parity rate has risen against the dollar for a three consecutive trading days.China's central bank announced on June 19 last year that it would further reform the yuan exchange rate formation mechanism to improve its flexibility.On China's foreign exchange spot market, the yuan can rise or fall 0.5 percent from the central parity rate each trading day.The central parity rate of the RMB against the U.S. dollar is based on a weighted average of prices before the opening of the market each business day.

BEIJING, Feb. 8 (Xinhua) -- China's aviation authorities announced on Tuesday that more passengers traveled by air during the Spring Festival holidays, with Chinese airlines handling some 5.07 million passengers during the period.The number of passengers on flights during the Chinese Lunar New Year holidays, which ended Tuesday, was up 6 percent from the same period last year, according to the Civil Aviation Administration of China (CAAC).On average, 72 percent of the seats on flights across the country were loaded during the holiday travel season, up 2 percentage points from the same period last year, according to the CAAC.To prepare for the holiday travel surge, the CAAC arranged 38,992 flights during the holidays, including eight chartered flights to Egypt to fly home 1,796 Chinese travelers stranded amid massive protests in the African country.
WASHINGTON, March 25 (Xinhua) -- Researchers at the University of Colorado (CU) and the Harvard University have found that people living at higher altitudes have a lower chance of dying from ischemic heart disease and tend to live longer than others, according to a study published this week in the Journal of Epidemiology and Community Health.They spent four years analyzing death certificates from every county in the United States. They examined cause-of-death, socio- economic factors and other issues in their research.They found that of the top 20 counties with the highest life expectancy, eleven for men and five for women were located in Colorado and Utah. And each county was at a mean elevation of 5, 967 feet above sea level. The men lived between 75.8 and 78.2 years, while women ranged from 80.5 to 82.5 years.Compared to those living near sea-level, the men lived 1.2 to 3. 6 years longer and women 0.5 to 2.5 years more."If living in a lower oxygen environment such as in our Colorado mountains helps reduce the risk of dying from heart disease it could help us develop new clinical treatments for those conditions," said Benjamin Honigman, professor of Emergency Medicine at the CU School of Medicine. "Lower oxygen levels turn on certain genes and we think those genes may change the way heart muscles function. They may also produce new blood vessels that create new highways for blood flow into the heart."Another explanation, he said, could be that increased solar radiation at altitude helps the body better synthesize vitamin D which has also been shown to have beneficial effects on the heart and some kinds of cancer.Despite these numbers, the study showed that when socio- economic factors, solar radiation, smoking and pulmonary disease were taken into account, the net effect of altitude on overall life expectancy was negligible.Still, Honigman said, altitude seems to offer protection against heart disease deaths and may also play a role in cancer development.Colorado, the highest state in the nation, is also the leanest state, the fittest state, has the fewest deaths from heart disease and a lower incidence of colon and lung cancer compared to others.
BEIJING, March 27 (Xinhua) -- China's search giant Baidu has pledged to remove all unauthorized literary works from its free online literary database Wenku within three days.After receiving requests from copyright owners to remove their works, Baidu has sped up its process of checking for unauthorized items. The unauthorized works were uploaded by Internet users to Wenku without prior approval from the authors, a spokesman for the Chinese search engine giant said in a statement.In the statement issued Saturday, Baidu apologized for what has "hurt the feelings of a certain number of writers" during Wenku's previous stage of operation, according to a report published Sunday by daily newspaper The Beijing News.Baidu said it respects copyright laws and will continue to cooperate with publishers and writers to establish a revenue-sharing model that will ensure that copyright owners receive a share of revenues from online versions of their works.Hailing Baidu's move to remove the unauthorized works, Wang Yefei, deputy head of Beijing Municipal Bureau of Copyrights hopes that Baidu and the publishers should work together to find win-win methods of mutual cooperation, according to the newspaper.However, some writers involved in the copyright row are dissatisfied with remedies Baidu has so far taken.Shen Haobo, CEO of Beijing Motie Book Co. Ltd, one of the six negotiators representing writers in Thursday's negotiations, told the Beijing Youth Daily that Baidu apologized only because of public pressure, but it did not mean to alter its current operation model for Wenku."Without changes in the operation model, the unauthorized works, even if removed now, could be uploaded again sometime later. Besides, it's unacceptable that Baidu reiterated that it had not infringed on our copyright," Shen was quoted as saying.Popular writer and blogger Han Han posted an open letter he wrote to Baidu's CEO Li Yanhong in his blog, indicating that he might take further actions to uphold his rights if Baidu's stance remains unchanged.Baidu's online literary database Wenku is an open platform for online resource sharing. It has been in operation since 2009.More than 40 Chinese writers posted an open letter online on March 15, accusing Baidu of stealing their works and infringing on their copyrights. Baidu's Wenku database was blamed for allowing literary works to become available online without the authors' prior approval.Baidu was asked to make a public apology, compensate for the writers' losses and halt any cases of copyright infringement.
来源:资阳报